我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效观察(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2003年第5期
页码:
423-424,427
栏目:
临床研究
出版日期:
2003-09-01

文章信息/Info

Title:
The therapeutic effect of co-administration of aspirin and ticlopidine and low molecular weight heparin on patients with unstable angina pectoris
作者:
陈旭昌; 何勇; 张军; 郑强荪
第四军医大学唐都医院心内科, 陕西 西安 710038
Author(s):
CHEN Xu-chang;  HE Yong;  ZHANG Jun;  ZHENG Qiang-sun
Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, China
关键词:
阿司匹林; 噻氯匹啶; 低分子肝素; 不稳定型心绞痛
Keywords:
aspirin;  ticlopidine;  low molecular weight heparin;  angina pectoris;  unstable
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:评价在阿司匹林与噻氯匹啶合用基础上使用低分子肝素治疗不稳定型心绞痛疗效及安全性。方法: 不稳定型心绞痛90例随机分成3组,A组为常规治疗组, 给予口服阿司匹林, 每天100mg; B组为A组加服噻氯匹啶。每天250mg; C组为在B组治疗基础上, 给予皮下注射低分子肝素, 每次0.4ml (4100 U AXaWHO 单位) , 除第1天12h 1 次外, 每天1 次。疗程均为7 d。各组均给予硝酸酯类、B受体阻滞剂、钙拮抗剂。结果: A、B、C 3 组总有效率分别为57%、63%、90% ,C 组总有效率与A 组比较有显著性差异(P<0.01)。随访30 d, C 组急性心脏事件发生率明显低于A 组(P<0.05) , 与B 组无显著性差异(P> 0.05)。不良反应, 3 组间无显著性差异(P>0.05)。结论: 阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效确切, 使用安全, 且能减少急性心脏事件发生率。
Abstract:
AIM: To evaluate clinical effect of co-administration of aspirin, ticlopidine and low molecular weight heparin (LMWH) on unstable angina pectoris (UAP). METHODS: 90 UAP cases were randomly divided into the control aspirin group , the aspirin and ticlopidine group and the treated group (aspirin and ticlopidine combined with LMWH). The therapeutic course was one week. RESULTS: The effective rate was 90% in the treated group , 63% in the aspirin and ticlopidine group, and 57% in the control group after one weeks treatment. The effective rate was significantly higher in the treated group than in the control group (P<0.01). The incidence of cardiac events was significantly lower in the treated group than in the control group (P<0105). CONCLUSION: Aspirin, ticlopidine and LMWH combined with normal treatment can effectively control angina pectoris and decrease incidence of cardiac event.

参考文献/References

[1] Nuredn P, Bihour C, Smith M, et al. Platelet activation and thrombosis: studies in patients with essential thrombocythemia [J] . Am J Hematol, 1996, 51:79-84.

[2] Luisa-Gregorini J, Marl O, et al. Ticlopidine and aspirin pretreatment reduce coagulation and platelet activation during coronary dilation procedures [J]. JACC, 1997, 29:13-20.

[3] Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J] . Nature, 1998, 391:591-594.

[4] Biasucci LM, Luizzo G, Grillo RL, et al. Elevated Levels of Creactive protein at discharge in patients with unstable angina predict recurrent in-stability [J] . Circulation, 1999, 99:855-860.

[5] 曾国彬, 张玉顺, 贾国良. 低分子肝素治疗不稳定型心绞痛的疗效[J]. 心脏杂志, 2001, 13(3):206-208.

[6] 封金伟, 吕艳青. 低分子肝素钙治疗不稳定型心绞痛的疗效观察 [J] . 心脏杂志, 2001, 13(1):67.

[7] 夏云峰, 刘润梅, 翟红霞, 等. 肝素在老年不稳定型心绞痛患者中的应用 [J] . 心脏杂志, 2001, 13(2):159.

[8] 张旭环, 王志坚. 低分子肝素治疗不稳定型心绞痛的疗效观察 [J] . 心脏杂志, 2002, 14(1):88.

备注/Memo

备注/Memo:
收稿日期：2003-01-09.
更新日期/Last Update: 2003-09-01